- Home
- NTB vs NUVB Comparison
NTB vs NUVB Comparison
Compare NTB & NUVB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NTB
- NUVB
- Stock Information
- Founded
- NTB 1858
- NUVB 2018
- Country
- NTB Bermuda
- NUVB United States
- Employees
- NTB N/A
- NUVB N/A
- Industry
- NTB Commercial Banks
- NUVB Biotechnology: Pharmaceutical Preparations
- Sector
- NTB Finance
- NUVB Health Care
- Exchange
- NTB Nasdaq
- NUVB Nasdaq
- Market Cap
- NTB 1.9B
- NUVB 1.6B
- IPO Year
- NTB 2016
- NUVB N/A
- Fundamental
- Price
- NTB $46.09
- NUVB $4.85
- Analyst Decision
- NTB Hold
- NUVB Strong Buy
- Analyst Count
- NTB 3
- NUVB 7
- Target Price
- NTB $50.67
- NUVB $8.86
- AVG Volume (30 Days)
- NTB 238.0K
- NUVB 9.2M
- Earning Date
- NTB 10-28-2025
- NUVB 11-03-2025
- Dividend Yield
- NTB 4.34%
- NUVB N/A
- EPS Growth
- NTB 17.07
- NUVB N/A
- EPS
- NTB 5.27
- NUVB N/A
- Revenue
- NTB $599,452,000.00
- NUVB $26,748,000.00
- Revenue This Year
- NTB $4.46
- NUVB $283.17
- Revenue Next Year
- NTB N/A
- NUVB $340.98
- P/E Ratio
- NTB $8.77
- NUVB N/A
- Revenue Growth
- NTB 4.60
- NUVB 1137.19
- 52 Week Low
- NTB $34.77
- NUVB $1.54
- 52 Week High
- NTB $46.92
- NUVB $5.55
- Technical
- Relative Strength Index (RSI)
- NTB 62.61
- NUVB 59.61
- Support Level
- NTB $45.21
- NUVB $4.53
- Resistance Level
- NTB $46.89
- NUVB $5.17
- Average True Range (ATR)
- NTB 1.02
- NUVB 0.45
- MACD
- NTB 0.24
- NUVB -0.05
- Stochastic Oscillator
- NTB 83.32
- NUVB 61.04
About NTB Bank of N.T. Butterfield & Son Limited (The) Voting
Bank of N.T Butterfield & Son Ltd is a full-service bank and wealth manager. It operates the business through three geographic segments, Bermuda, Cayman Islands, the Channel Islands and the UK. The company offers banking services, comprised of retail and corporate banking, and wealth management, which consists of trust, private banking, and asset management. The company generates a majority of its revenue from Bermuda, and the Cayman Islands segments.
About NUVB Nuvation Bio Inc.
Nuvation Bio Inc is a biopharmaceutical company tackling unmet needs in oncology by developing differentiated and novel therapeutic candidates. Its product candidate, taletrectinib, is an oral, potent, central nervous system-active, selective, next-generation c-ros oncogene 1 (ROS1) inhibitor specifically designed for the treatment of patients with ROS1+ non-small cell lung cancer (NSCLC). In addition, its clinical-stage pipeline includes differentiated, novel oncology product candidates such as Safusidenib, NUV-1511, and NUV-868 in their different stages of development. The company generates revenue through out-licensing collaborative agreements with its customers located in China and Japan.